Literature DB >> 18849321

Informed consent revisited: a doctrine in the service of cancer care.

Madeleine Schachter1, Joseph J Fins.   

Abstract

Informed consent traditionally has been viewed as a safeguard for the protection of patients' decisional autonomy. While informed consent is a critical means for the protection of the patient's dominion over the integrity of his body, exclusive consideration of the doctrine as a safeguard for patients eclipses the doctrine's significant benefits for the therapeutic endeavor. Undertaking a thorough informed consent process helps the physician avoid the unilateral burdens of paternalism; furthers compliance with the doctor's legal obligations, ethical duties, and clinical responsibilities; and, as importantly, enhances the collaborative treatment enterprise. When informed consent is viewed narrowly and solely as a protective device for patients' rights, the physician may be less likely to engage the patient in ongoing discussions. Important opportunities may be missed to elicit additional clinical information, assess psychosocial concerns, and reiterate the commitment to collaboration and patient autonomy.

Entities:  

Mesh:

Year:  2008        PMID: 18849321     DOI: 10.1634/theoncologist.2008-0101

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  3 in total

1.  Making an informed decision of Korean cancer patients: the discrepancy between a patient's recall of information and the information needed for acquisition of radiotherapy informed consent.

Authors:  Hye Ran Lee; Chiyeon Lim; Hyong Geun Yun; Seung Hee Kang; Do Yeun Kim
Journal:  Support Care Cancer       Date:  2017-08-08       Impact factor: 3.603

2.  Using virtual reality to provide health care information to people with intellectual disabilities: acceptability, usability, and potential utility.

Authors:  Valerie Hall; Suzanne Conboy-Hill; Dave Taylor
Journal:  J Med Internet Res       Date:  2011-11-14       Impact factor: 5.428

3.  The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study.

Authors:  Harun Badakhshi; Arne Gruen; Jalid Sehouli; Volker Budach; Dirk Boehmer
Journal:  Cancer Med       Date:  2013-08-20       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.